gastroesophageal adenocarcinoma
gastroesophageal adenocarcinoma
Explore linked clinical trials. Standard reference: MONDO:085013021 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06) | Digestive System Diseases, Digestive System Neoplasms, Esophageal Neoplasms, Head and Neck Neoplasms, Neoplasms by Site, autosomal dominant Parkinson disease 4, digestive system disorder, digestive system neoplasm, esophageal cancer, esophageal disorder, gastroesophageal adenocarcinoma, neoplasm | Recruiting | Phase 1 / Phase 2 | 2026-10-07 | NCT06469944 | |
| A Phase 1 Study Evaluating DISP-10 in Participants With Advanced Gastrointestinal Cancers | DNA Virus Infections, Digestive System Diseases, Digestive System Neoplasms, Infections, Neoplasms by Site, adenoviridae infectious disease, colonic disorder, colorectal cancer, colorectal neoplasm, digestive system disorder, digestive system neoplasm, esophageal adenocarcinoma, gastric adenocarcinoma, gastroesophageal adenocarcinoma, intestinal disorder, neoplasm, rectal disorder, viral infectious disease | Recruiting | Phase 1 | 2026-10-05 | NCT07544589 | |
| AACR Adaptive Biomarker-Driven Organ Preservation Trial in Gastroesophageal Adenocarcinomas | gastroesophageal adenocarcinoma | Recruiting | Phase 2 | 2026-10-05 | NCT07290985 | |
| Phase 1/2 Study of BHB810 in Advanced Gastric and GEJ Adenocarcinoma | Cancer of Gastrointestinal Tract, Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, adenocarcinoma, carcinoma, colonic disorder, colonic neoplasm, colorectal neoplasm, digestive system disorder, digestive system neoplasm, endocrine system disorder, epithelial neoplasm, gastric adenocarcinoma, gastric cancer, gastric neoplasm, gastroesophageal adenocarcinoma, intestinal disorder, malignant endocrine neoplasm, malignant pancreatic neoplasm, neoplasm, pancreas disorder, pancreatic neoplasm, stomach disorder | Recruiting | Phase 1 / Phase 2 | 2026-10-02 | NCT07529808 | |
| A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, digestive system disorder, digestive system neoplasm, gastric neoplasm, gastroesophageal adenocarcinoma, neoplasm, stomach disorder | Recruiting | Phase 2 | 2026-09-24 | NCT07069712 | |
| A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers | Digestive System Diseases, Digestive System Neoplasms, Esophageal Neoplasms, Head and Neck Neoplasms, Neoplasms by Site, autosomal dominant Parkinson disease 4, digestive system disorder, digestive system neoplasm, esophageal adenocarcinoma, esophageal disorder, gastric neoplasm, gastroesophageal adenocarcinoma, neoplasm, stomach disorder | Active, not recruiting | Phase 3 | 2026-09-24 | NCT05152147 | |
| Personalized Cancer Vaccine (PCV) Strategy in Patients With Solid Tumors and Molecular Residual Disease | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Skin and Connective Tissue Diseases, Thoracic Neoplasms, Urogenital Diseases, Urogenital Neoplasms, benign urinary system neoplasm, bronchial neoplasm, bronchogenic carcinoma, gastroesophageal adenocarcinoma, lung disorder, lung neoplasm, melanocytic neoplasm, melanoma, neoplasm, neuroendocrine neoplasm, non-small cell lung carcinoma, primitive neuroectodermal tumor, respiratory system disorder, respiratory tract neoplasm, skin disorder, skin neoplasm, urinary bladder disorder, urinary bladder neoplasm, urinary system disorder | Recruiting | Phase 1 | 2026-09-21 | NCT06529822 | |
| Trial Comparing Standard of Care Therapy With and Without Sequential Cytoreductive Intervention for Patients With Metastatic Foregut Adenocarcinoma and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid (ctDNA) Levels | Neoplasms by Histologic Type, adenocarcinoma, ampulla of vater adenocarcinoma, carcinoma, cholangiocarcinoma, duodenal adenocarcinoma, epithelial neoplasm, esophageal adenocarcinoma, gallbladder adenocarcinoma, gastric adenocarcinoma, gastroesophageal adenocarcinoma, neoplasm, pancreatic adenocarcinoma | Recruiting | Phase 2 | 2026-09-08 | NCT07282912 | |
| Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06) | Digestive System Diseases, Digestive System Neoplasms, Esophageal Neoplasms, Head and Neck Neoplasms, Neoplasms by Site, autosomal dominant Parkinson disease 4, digestive system disorder, digestive system neoplasm, esophageal cancer, esophageal disorder, gastroesophageal adenocarcinoma, neoplasm | Recruiting | Phase 1 / Phase 2 | 2026-09-03 | NCT06445972 | |
| A First-in-Human Study of HH160 in Participants With Advanced or Metastatic Solid Tumors | Adnexal Diseases, Digestive System Diseases, Digestive System Neoplasms, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Head and Neck Neoplasms, Liver Neoplasms, Male Urogenital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Skin and Connective Tissue Diseases, Thoracic Neoplasms, Urogenital Diseases, Urogenital Neoplasms, Uterine Cervical Neoplasms, adenocarcinoma, benign urinary system neoplasm, breast disorder, breast neoplasm, bronchial neoplasm, bronchogenic carcinoma, carcinoma, cervix disorder, colonic disorder, colorectal cancer, colorectal neoplasm, digestive system disorder, digestive system neoplasm, endocrine system disorder, endometrium neoplasm, epithelial neoplasm, female reproductive system disorder, female reproductive system neoplasm, gastroesophageal adenocarcinoma, gonadal disorder, head and neck squamous cell carcinoma, hepatocellular carcinoma, intestinal disorder, kidney cancer, kidney disorder, liver disorder, lung disorder, lung neoplasm, malignant endocrine neoplasm, neoplasm, non-small cell lung carcinoma, ovarian cancer, ovarian disorder, rectal disorder, renal cell carcinoma, respiratory system disorder, respiratory tract neoplasm, skin disorder, small cell lung carcinoma, squamous cell carcinoma, transitional cell carcinoma, triple-negative breast carcinoma, urinary system disorder, urothelial carcinoma, uterine disorder | Recruiting | Phase 1 | 2026-08-21 | NCT07623369 | |
| Phase II Study of Short Course FOLFOX Chemotherapy With Either Nivolumab or Nivolumab + Radiation in the First Line Treatment of Metastatic or Unresectable Gastroesophageal Cancers (BMS Protocol CA209-76L) | gastroesophageal adenocarcinoma | Active, not recruiting | Phase 2 | 2026-08-21 | NCT04021108 | |
| Paclitaxel, Ramucirumab and Tislelizumab Switch Maintenance in Advanced HER2-negative and PD-L1 TAP Score of 5 or More Advanced Gastroesophageal Adenocarcinoma | gastroesophageal adenocarcinoma | Not yet recruiting | Phase 3 | 2026-08-18 | NCT07763171 | |
| Paclitaxel and Ramucirumab +/- Zanidatamab in HER2 Postive Advanced Gastroesophageal Adenocarcinoma | gastroesophageal adenocarcinoma | Recruiting | Phase 2 | 2026-08-11 | NCT06043427 | |
| RESTAGE (REpurposing STAtins to Improve Outcomes in GastroEsophageal Cancer) Trial | Digestive System Diseases, Digestive System Neoplasms, Esophageal Neoplasms, Head and Neck Neoplasms, Neoplasms by Site, digestive system disorder, digestive system neoplasm, esophageal disorder, gastroesophageal adenocarcinoma, neoplasm | Not yet recruiting | Phase 2 | 2026-07-10 | NCT07625930 | |
| Zanidatamab in Combination With Pembrolizumab and Chemotherapy in HER2 and PD-L1 Positive Metastatic Gastroesophageal Adenocarcinoma (GEA) Patients | Digestive System Diseases, Digestive System Neoplasms, Neoplasm Metastasis, Neoplasms by Site, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, digestive system disorder, digestive system neoplasm, gastric neoplasm, gastroesophageal adenocarcinoma, neoplasm, stomach disorder | Recruiting | Phase 2 | 2026-06-30 | NCT07176312 | |
| Response Adapted Neoadjuvant Therapy in Gastroesophageal Cancers (RANT-GC Trial) | gastroesophageal adenocarcinoma | Recruiting | Phase 1 | 2026-03-10 | NCT05733689 | |
| Adebrelimab Combined With Induction Chemotherapy or SHR-8068 for Mismatch Repair-Deficient/Microsatellite Instability-High (dMMR/MSI-H) Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma：A Randomized, Non-comparative Phase 2 Study | gastric adenocarcinoma, gastroesophageal adenocarcinoma, mismatch repair cancer syndrome 1 | Not yet recruiting | Phase 2 | 2026-01-27 | NCT07266025 | |
| A First-in-Human Study Using BDC-4182 as a Single Agent in Advanced Gastric and Gastroesophageal Cancer | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, digestive system disorder, digestive system neoplasm, gastric neoplasm, gastroesophageal adenocarcinoma, neoplasm, stomach disorder | Recruiting | Phase 1 / Phase 2 | 2026-01-27 | NCT06921837 | |
| Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 as Monotherapy and in Combination With IV Bevacizumab | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, colonic disorder, colorectal cancer, colorectal neoplasm, digestive system disorder, digestive system neoplasm, gastroesophageal adenocarcinoma, intestinal disorder, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, rectal disorder, respiratory system disorder, respiratory tract neoplasm | Active, not recruiting | Phase 1 | 2025-10-29 | NCT05029882 | |
| A Clinical Trial Evaluating TQB2102 for Injection in Combination With Behmosubaisumab/Payamprolizumab With or Without Chemotherapy in Unresectable Locally Advanced, Recurrent, or Metastatic Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastroesophageal Adenocarcinoma | gastroesophageal adenocarcinoma | Recruiting | Phase 2 | 2025-07-30 | NCT06767800 | |
| Adebrelimab With Chemoradiotherapy and Surgery for G/GEJ | gastric adenocarcinoma, gastroesophageal adenocarcinoma | Recruiting | Phase 2 | 2025-05-22 | NCT06985602 |